{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:14:30Z","timestamp":1776705270671,"version":"3.51.2"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijantimicag.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T12:25:07Z","timestamp":1517574307000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae"],"prefix":"10.1016","volume":"51","author":[{"given":"Barbara A.","family":"Santevecchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffeny T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn H.","family":"MacVane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0020","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00449-17","article-title":"Outcomes with ceftazidime\/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections: a multi-center study","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0040","first-page":"1","article-title":"Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterization","volume":"22","author":"Krapp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0045","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0050","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0060","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0065","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"12","author":"Khwaja","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0070","series-title":"Avycaz (ceftazidime and avibactam)","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0075","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement (M100-S26)","author":"Clinical Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0080","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u2018sepsis-related problems\u2019 of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CCM.0000000000001375","article-title":"Validity of a modified sequential organ failure assessment score using the Richmond Agitation-Sedation Scale","volume":"44","author":"Vasilevskis","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.01.016_bib0090","unstructured":"Santevecchi B.A., Steed L.L., Bosso J.A. Determination of carbapenem resistant Enterobacteriaceae resistance mechanisms. Poster presented at: The 20th Annual MAD-ID Meeting; May 11, 2017; Orlando, FL."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T03:28:55Z","timestamp":1603769335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918300190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0924857918300190"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}